9.00-9.05             Welcome & introduction - Harry Janssen

Liver tumors - Chair Dave Sprengers

9.05-9.35             Role of biomarkers in HCC surveillance - Xavier Verhelst 

9.35-9.55             Role of SBRT - Alejandra Mendez Romero

9.55-10.15           MASLD and liver tumors - Willem Pieter Brouwer

10.15-10.30         Discussion + Q&A

10.30-11.00         Break

Interventional hepatology - Chair Anne van Eldere

11.00-11.30         New endoscopic procedures in hepatology - Jonel Trebicka 

11.30-11.50         To scope or not to scope in cirrhotic patients? Raoel Maan

11.50-12.05         Discussion + Q&A

​

12.05-13.05         Lunch

​

Liver failure and liver transplantation / ACLF - Chair Caroline den Hoed

13.05-13.10         Solko Schalm Award Ceremony

13.10-13.40         Alcohol and liver transplantion - Marina Berenguer 

13.40-14.10         ACLF: to transplant or not? Thierry Artzner 

14.10-14.30         Loose ends on HCV management: vaccination, decompensation and transplantation - Jordan Feld

14.30-14.45         Discussion + Q&A 

​

14.45-15.00         Break

​

Latest drugs in liver disease - chair Harry Janssen

15.00-15.20         Metabolic drugs in steatosis - Mariëtte Boon 

15.20-15.40         New HBV and HDV treatment: viral suppression or cure? Milan Sonneveld

15.40-16.00         Developments in autoimmune liver diseases - Adriaan van der Meer

16.00-16.15         Discussion + Q&A

​​

16.15-16.20         Closing remarks - Harry Janssen

16.20                   Drinks